A Chatbot to Support Substance Use Recovery

Dimagi

Status and phase

Enrolling

Phase 2

Phase 1

Conditions

Opiate Substitution Treatment

Opiate-Related Disorders

Treatments

Other: chatbot

Study type

Interventional

Funder types

Other

Industry

NIH

Identifiers

NCT06845878

2R44DA050218-02 (U.S. NIH Grant/Contract)

2R44DA050218 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The goal of this clinical trial is to learn if/how an AI chatbot can support patients who in recovery for substance use, specifically those who are receiving medication for opioid use disorder.

Can the chatbot help lower drug use? Can the chatbot help improve clinical appointment adherence? Can the chatbot help patients build self-efficacy in leading their own recovery journey? Will the chatbot help reduce workload burden for primary care teams? Can the chatbot serve as a safe, useful and engaging tool to support patients?

Researchers will investigate the effects of using a chatbot to support follow-up care for patients in opioid use recovery.

Participants will:

Receive access to a chatbot for 12 weeks that they can use to prepare for upcoming clinical appointments, find community resources, learn about urge-surfing and wellness techniques, and query for assistance with other recovery-related information and tasks
Complete surveys and provide user feedback

Enrollment

55 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18-65 years old
Comfortable with reading, understanding, and communicating in English
Receiving medication treatment for OUD at MGH?
Able to participate in a remote interview?
Own or have reliable access to Wi-Fi or a cellular network
Willing to use a mobile device to access the chatbot?

Exclusion criteria

Has any cognitive, visual, or auditory impairments that may prevent the participant from using the chatbot on a mobile device?
Unstable medical condition that compromises the ability to safely participate